Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
I wrote a blog post about once about key questions to ask about your multiple myeloma when you are newly diagnosed. Staging of MM is essential to understanding your multiple myeloma prognosis.
Likewise, according to the article linked below, is your cytogenetic prognostic index. A MM patient’s CPI, however, is way beyond that staging that I was refering to when I wrote the “questions” blog post.
Beyond knowing your genetic abnormalities, I don’t see how your decision-making as a MM patient will be affected one way or another by knowing your CPI.
What I do think will positively affect your decision-making is if you work with (at least consult with) a MM specialist rather than a regular hemotologist-oncologist. I think that MM specialists will understand how your genetic abnormalties will effect various combinations of chemotherapy regimens as well as your MM prognosis.
Keep in mind that our genetic expression, how our genes express themselves, can change. And this change can affect your MM prognosis.
Have you been diagnosed with multiple myeloma? What stage? What cytogenetic abnormalities, if any? Are you working with a MM specialist?
Scroll down the page, post a question or comment and I will reply to you ASAP.
“The wide heterogeneity in multiple myeloma (MM) outcome is driven mainly by cytogenetic abnormalities. The current definition of high-risk profile is restrictive and oversimplified. To adapt MM treatment to risk, we need to better define a cytogenetic risk classification. To address this issue, we simultaneously examined the prognostic impact of
in a cohort of newly diagnosed patients with MM…